Fabtech Technologies Ltd Q1 FY27 Results & Concall Highlights: Revenue ₹9300 Cr

Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹673 Cr

Fabtech Technologies aims for 20-25% year-on-year organic growth. Fabtech Technologies targets 20-25% year-on-year organic growth going forward (Page 9, 18, 21). - PAT guidance for current year is 9-11%, with aspirations toward 9.5-10% in the near term and 12% next year (Page 18). - Company aims for gradual margin expansion driven by a combination of gross margin improvement and operating leverage (Page 21). - Improvement in contribution margin was seen recently, expanding by ~900 basis points to 46.7% (Page 8). - Long-term vision includes reaching a 1000+ crore revenue mark by 2030 through organic growth (Page 18). - The business is seasonal with H2 typically stronger; growth in H2 is expected to be stronger than H1 (Page 9). - Company is working on contracts to shift revenue recognition more towards percentage completion method, which may improve profitability visibility (Page 20). - Profitability turnaround seen with net profit of Rs.

From Fabtech Technologies Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Price

147

Market Cap

₹673 Cr

P/E Ratio

13.8

Revenue Rank

Rank 2

Margin Rank

Rank 2

How does Fabtech Technologies Ltd rank in Healthcare Services?

Compare Fabtech Technologies Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 2Margin: Rank 2
View Healthcare Services leaderboard →

Fabtech Technologies Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹159 Cr, net profit ₹22 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 2
  • Fabtech Technologies aims for 20-25% year-on-year organic growth.
  • Target to achieve ₹1000 crore+ top-line by 2030, considered a conservative estimate.
  • Q2 is expected to be steady, with stronger H2 performance typically seen in the EPC design and build industry.
  • Active inquiries exceed ₹9300 crore with hot leads over ₹3800 crore, providing two-year sales visibility.
  • Growth driven by deeper localization, pipeline conversion with disciplined order selection focusing on quality, and integration of acquisitions to boost local execution.
  • Expansion into GCC, Eastern and Southern Africa markets, notably through Fabtech Life Care in Saudi Arabia.
  • Large ticket opportunities delayed due to geopolitical factors, but no cancellations, with ongoing client engagement.
  • Focus on profitable growth with disciplined execution and working capital efficiency.

📈 Profitability & Margins

Rank 2
  • Fabtech Technologies targets 20-25% year-on-year organic growth going forward (Page 9, 18, 21).
  • PAT guidance for current year is 9-11%, with aspirations toward 9.5-10% in the near term and 12% next year (Page 18).
  • Company aims for gradual margin expansion driven by a combination of gross margin improvement and operating leverage (Page 21).
  • Improvement in contribution margin was seen recently, expanding by ~900 basis points to 46.7% (Page 8).
  • Long-term vision includes reaching a 1000+ crore revenue mark by 2030 through organic growth (Page 18).
  • The business is seasonal with H2 typically stronger; growth in H2 is expected to be stronger than H1 (Page 9).
  • Company is working on contracts to shift revenue recognition more towards percentage completion method, which may improve profitability visibility (Page 20).
  • Profitability turnaround seen with net profit of Rs. 4.21 crores in Q1 FY27 from a loss last year (Page 8).

🏗️ Capital Expenditure Plans

Yes
  • Fabtech Technologies Limited has made strategic acquisitions to support growth:
  • - Acquired majority stake in Specialized Activities Contracting Establishment (SACE) in Saudi Arabia for local presence and bidding on HVAC MEP and civil projects.
  • - Ongoing due diligence for a European acquisition expected to drive future market entry, with completion anticipated within 2-3 quarters.
  • Capital allocation focuses on execution, with working capital released only when order book growth and project requirements align.
  • Acquisitions are strategically fit-driven, with capital deployment following due diligence and integration suitability.
  • Investments post-IPO have been made in leadership and operational excellence.
  • Technology investments include digital tools, 3D modeling, and AI integration to improve project delivery timelines.
  • No specific high-value Greenfield CAPEX amount mentioned, but focus on profitable and disciplined growth with working capital efficiency.

💰 Fundraising & Capital Structure

No information
  • The document does not explicitly mention any current or planned new fundraising through debt or equity.
  • Capital allocation is focused on execution and strategic acquisitions only after due diligence.
  • Idle capital is currently held in fixed deposits (FT) awaiting suitable acquisition opportunities.
  • There is emphasis on organic growth and deploying capital based on project requirements and order book growth.
  • Management is concentrated on profitable, disciplined growth rather than raising new funds immediately.
  • Acquisitions will be funded only when a strategic fit is confirmed through due diligence, indicating a cautious approach to fundraising.

📋 Order Book & Pipeline

Yes
  • The current open order book is reported to be over ₹900 crores (approximately ₹920+ crores considering exchange rate fluctuations).
  • During Q1 FY27, new order inflows of ₹96.5 crores were added, while around ₹75 crores of orders were delivered.
  • Order book revenue recognition does not occur evenly across quarters; Q1 is typically the lightest in revenue due to milestone-based recognition.
  • Active inquiries exceed ₹9,300 crores in the total addressable funnel.
  • Hot leads, representing advanced commercial or technical opportunities with a path to conversion, are valued over ₹3,800 crores.
  • Some large-ticket opportunities have slipped due to geopolitical conditions and funding cycles but with no cancellations.
  • The company has a two-year visibility on its pipeline and is focused on quality order conversion over volume.

Key Metrics

Revenue

Rank 2

Margin

Rank 2

Capex

Yes

Fundraise

No information

Order Book

Yes

Frequently Asked Questions

What were Fabtech Technologies Ltd Q1 FY27 results?

Fabtech Technologies aims for 20-25% year-on-year organic growth. Fabtech Technologies targets 20-25% year-on-year organic growth going forward (Page 9, 18, 21). - PAT guidance for current year is 9-11%, with aspirations toward 9.5-10% in the near term and 12% next year (Page 18). - Company aims for gradual margin expansion driven by a combination of gross margin improvement and operating leverage (Page 21). - Improvement in contribution margin was seen recently, expanding by ~900 basis points to 46.7% (Page 8). - Long-term vision includes reaching a 1000+ crore revenue mark by 2030 through organic growth (Page 18). - The business is seasonal with H2 typically stronger; growth in H2 is expected to be stronger than H1 (Page 9). - Company is working on contracts to shift revenue recognition more towards percentage completion method, which may improve profitability visibility (Page 20). - Profitability turnaround seen with net profit of Rs.

What is Fabtech Technologies Ltd share price analysis?

Fabtech Technologies Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 13.8 with a market cap of ₹673 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fabtech Technologies Ltd planning capital expenditure?

Fabtech Technologies Limited has made strategic acquisitions to support growth: - Acquired majority stake in Specialized Activities Contracting Establishment (SACE) in Saudi Arabia for local presence and bidding on HVAC MEP and civil projects.

Keep Fabtech Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Fabtech Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q1 FY27)

    Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10). Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1…

  • Dr Lal Pathlabs (Q1 FY27)

    140 crore to Rs. Key concall takeaways from Dr Lal Pathlabs's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Vimta Labs Ltd (Q1 FY27)

    The company's various business units are growing at almost double the industry's CAGR (8%-11%). Key concall takeaways from Vimta Labs Ltd's Q1 FY27 earnings…

  • Dr Agarwal's Hea (Q1 FY27)

    Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Key concall takeaways from Dr…